Bergaptol, a mechanism-based inactivator of CYP2C9

被引:3
作者
Jiang, Tingting [1 ,2 ]
Cheng, Ting [1 ,2 ]
Li, Jing [1 ,2 ]
Zhou, Mengyue [1 ,2 ]
Tan, Rong [1 ,2 ]
Yang, Xiaojing [3 ]
Wang, Yang [1 ,2 ]
Li, Weiwei [1 ,2 ]
Zheng, Jiang [1 ,2 ,3 ,4 ]
机构
[1] Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, Guizhou Prov Key Lab Pharmaceut, Guiyang 550004, Guizhou, Peoples R China
[2] Guizhou Med Univ, Sch Pharm, Guiyang 550004, Guizhou, Peoples R China
[3] Shenyang Pharmaceut Univ, Sch Pharm, Wuya Coll Innovat, Shenyang 550025, Liaoning, Peoples R China
[4] Guizhou Med Univ, Key Lab Environm Pollut Monitoring & Dis Control, Minist Educ, Guiyang 550025, Guizhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Grapefruit; Bergaptol (BGT); Mechanism-based inactivation (MBI); Grape-drug interaction; GRAPEFRUIT JUICE; CYTOCHROME-P450; BIOSYNTHESIS; DERIVATIVES; INHIBITION; ENZYMES; 2C9;
D O I
10.1007/s00044-020-02564-x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Grapefruit-mediated fruit-drug interaction has been well discussed in clinical practice. However, the biochemical mechanisms for such interaction are far beyond our understanding. The objectives of the present study aimed at the interaction between bergaptol (BGT) and CYP2C9. BGT, one of the major furanocoumarin constituents in grapefruit, has been reported to inhibit the activity of CYP2C9. And a number of furan-containing compounds are known to act as mechanism-based inactivators of CYP2C9. In this study, BGT was found to induce time-, concentration-, and NADPH-dependent irreversible inhibition of CYP2C9. A GSH conjugate was detected in an incubation mixture containing CYP2C9, BGT, NADPH, and GSH. Further mechanistic investigation revealed that a gamma-ketoenal metabolite was responsible for the enzyme inactivation. The obtained data indicate that BGT was a mechanism-based inactivator of CYP2C9. The study would facilitate the understanding of the mechanistic insight into fruit-drug interactions mediated by grapefruits.
引用
收藏
页码:1230 / 1237
页数:8
相关论文
共 50 条
  • [21] The Role of Human CYP2C8 and CYP2C9 Variants in Pioglitazone Metabolism In Vitro
    Muschler, Eugen
    Lal, Jawahar
    Jetter, Alexander
    Rattay, Anke
    Zanger, Ulrich
    Zadoyan, Gregor
    Fuhr, Uwe
    Kirchheiner, Julia
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 (06) : 374 - 379
  • [22] Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans
    Honkalammi, J.
    Niemi, M.
    Neuvonen, P. J.
    Backman, J. T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (04) : 579 - 586
  • [23] 2,3,5,4?-Tetrahydroxy stilbene-2-O-?-D-glucoside, a mechanism-based inactivator of CYP2C19 and CYP3A4, potentiates hepatic protein adduction and hepatotoxicity induced by emodin in vivo
    Wang, Xu
    Dong, Lingwen
    Zhao, Guode
    Li, Weiwei
    Peng, Ying
    Zheng, Jiang
    CHEMICO-BIOLOGICAL INTERACTIONS, 2022, 368
  • [24] Effect of Dihydromyricetin on Cytochrome P450 Isoforms CYP1A2, CYP2C9 and CYP3A4 in Rats
    Huang, Yi
    Xu, Zhi-sheng
    Ye, Qiang
    LATIN AMERICAN JOURNAL OF PHARMACY, 2013, 32 (10): : 1570 - 1574
  • [25] Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants
    Hiratsuka, Masahiro
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (11) : 1748 - 1759
  • [26] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Lu, Sijie
    Nand, R. A.
    Yang, J. S.
    Chen, Gang
    Gross, A. S.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (03) : 285 - 296
  • [27] The inhibition of CYP1A2, CYP2C9, and CYP2D6 by pterostilbene in human liver microsomes
    Albassam, A. A.
    Ahad, A.
    Alsultan, A.
    Yusufoglu, H. S.
    Foudah, A., I
    Al-Jenoobi, F., I
    PHARMAZIE, 2021, 76 (04): : 155 - 158
  • [28] Response: Similar effect of quercetin on CYP2E1 and CYP2C9 activities in humans?
    Bedada, Satish Kumar
    Neerati, Prasad
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (09) : 1189 - 1190
  • [29] Esophageal cancer proliferation is mediated by cytochrome P450 2C9 (CYP2C9)
    Schmelzle, Moritz
    Dizdar, Levent
    Matthaei, Hanno
    Baldus, Stephan E.
    Wolters, Judith
    Lindenlauf, Nina
    Bruns, Ingmar
    Cadeddu, Ron-Patrick
    Kroepil, Feride
    Topp, Stefan A.
    Esch, Jan Schulte Am, II
    Eisenberger, Claus F.
    Knoefel, Wolfram T.
    Stoecklein, Nikolas H.
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2011, 94 (1-2) : 25 - 33
  • [30] The Inhibitory Effect of Telmisartan on the Metabolism of Arachidonic Acid by CYP2C9 and CYP2C8: An in Vitro Study
    Kato, Yuka
    Mukai, Yuji
    Rane, Anders
    Inotsume, Nobuo
    Toda, Takaki
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2017, 40 (09) : 1409 - 1415